



NEW EVIDENCE ON THE OUTCOME OF KCNQ2 PATIENTS

*THE IMPACT ON FAMILIES' LIVES FROM THE
FIRST EUROPEAN QUESTIONNAIRE*

INTRODUCTION

KCNQ2 variants are associated with a wide spectrum of disorders. The comorbidities have rarely been described as well as their impact on the lives of patients and their families has not yet been studied.

80

PATIENTS

40

MALES

14

COUNTRIES

7.6

AVERAGE AGE

Starting from a collaboration among caregivers from several European family associations, a questionnaire was developed to investigate the onset and frequency of epileptic seizures, anti epileptic drugs, hospitalization, developmental stages, and comorbidities.

Responses were collected from 80 patients, 40 males from 14 countries. Average age 7.6 year.

The document shows the results of the first European survey of patients with KCNQ 2. We were able to identify three different clusters of varying severity (Milder, Severe, Profound), based on neurodevelopmental characteristics and symptoms, excluding epilepsy. Patients belonging to a higher severity cluster had a higher average number of comorbidities, with a greater impact on families. The study also shows that patients belonging to different clusters had a different onset and course of epilepsy. Thanks to the European caregivers who administered the questionnaire and a team of neuropsychiatrists who analyzed the data, it is now possible to define the impact of the disease on the lives of patients and families and could help to identify new primary and secondary outcomes in addition to epileptic seizures in future studies.

GENETICS

80%

De novo variant



6%

Inherited mutation




14%


No information




MAIN FEATURES OF THE PATIENTS



Children age




Nationality



Quality of the Pregnancy

ABOUT SEIZURES

55% seizure free at the time of survey BUT **only 11** were **untreated**, which could suggest the **clinical necessity** of **continued treatment**, despite the drop in seizure frequency. The **reason** for **continuous ASM treatment**, especially in patients older than 13 years old, remain **clear**.





NEUROPSYCHOLOGICAL DEVELOPMENT


- AUTISM was diagnosed in 14% of cases
- 54% Poor social relationship of the child with peers
- 44% fair or good



FEEDING

- 94% were fed by mouth (75 children)
- 44% following a free diet
- 49% consuming semi-solid foods

FED BY MOUTH



MOTOR SKILLS

9 < 2 YEAR

- 4 compared to their peers
- 1 slightly delayed
- 4 moderately to severely delayed


>2 YEAR

- 25% could not keep their heads up (18/71)
- 15% could with support (11/71)
- 5% could sit down on their own but not stand up and walk with aid (4/71)
- 38% walk independently (27/71)


SPHINCTER CONTROL

- 75% unable (45/60)
- 3% alert when needed (2/60)
- 21% could retain control day and night (13/60)

MUSCLE TONE



LINGUISTIC SKILLS




Note: 71 responses




SLEEP

- **24%** of **families** used a **specific medication** to **facilitate falling asleep**
- Only **rarely caregiver** stated a **clear relationship** between **sleep** and the **recurrence of seizures**




REHABILITATION

40% undertook daily activities like sport, art, music therapy, equine-assisted therapy.




CAREGIVERS' PERSPECTIVE

The issues that impacted most the well-being of their child were **developmental delay** in 14% (11/80), followed by **movement disorder** in 11% (9/80) of cases, **seizures** in 7% (6/80) of cases, **muscle tone** in 6% (5/80) of cases and **language** in 5% (4/80). Other cited issues were **autism**, **pain**, **gastrointestinal issues**, **respiratory problems**, **vision**, **sleep issues**, **feeding issues**, and **osteoarticular problems**.



MAGNETIC RESONANCE IMAGING

The MRI found **an abnormality in 43%** (32/75) of cases. Among these findings, the families listed: hypomyelination in 37% (12/32), white matter abnormalities in 12% (4/32), cortical atrophy in 9% (3/32), malformation of cortical development in 6% (2/32), thin corpus callosum in 28% (9/32), and other nonspecific abnormalities in 50% (16/32) of patients.




CLUSTER ANALYSIS


A cluster analysis was considered with regard to motor skills, feeding abilities, muscle tone, language, presence of autism and motor stereotypies. These variables were analysed in the 71 patients over 2 years of age in order to obtain a more homogeneous developmental phenotype with comparable stages in motor and language development.

Milder phenotype: ability to walk, feeding by mouth with a diet of varying consistency, normal muscle tone or mild hypotonia and productive language. Lower incidence of epilepsy.

Severe phenotype: ability to sit and stand independently but not to walk, feeding on a diet of semi-solid consistency, spastic muscle hypertonia and language characterised by sounds or syllables. Lower incidence of autism diagnosis. Epilepsy in almost all cases.

Profound phenotype: inability to hold head up, feeding on semi-solid diet or PEG, variable muscle tone with hypotone and hypertone. All patients were non-verbal. None of them were diagnosed with autism, all patients were epileptic.





Interestingly, we found a difference within our sample in the reported age at seizure onset, with a higher frequency of patients presenting seizures in the first 10 hours of life in the profound phenotype cluster, while the high percentage of onset in the first day of life was retained across all clusters. Also, regarding epilepsy onset, a majority of patients with a reported burst-suppression pattern at first EEG belong to the Profound phenotype cluster.

Regarding seizure frequency, a higher portion of patients in the Milder cluster was reported seizure-free, compared to the other two groups. Among the patients who still presented seizures, patients in the Profound phenotype reported daily seizures more frequently, compared to the other clusters. Among the seizure free patients, the mean age at the last seizure was higher in patients in the Severe cluster.

Certain times of epilepsy onset and certain epilepsy features, seem to be associated with different phenotypical outcomes, possibly linked to genotype. A limitation of this study is, in fact, the lack of investigation of possible correlations between phenotype and the patients' variants and their functional effects. This could further help the grouping in more homogenous phenotypes, between gain-of-function and loss of-function carrying patients.

NOTE

Source of information and data mentioned in this document: Epilepsy & Behavior 142 (2023) 109153 “Clinical Characteristics of 80 subjects with KCNQ2-related encephalopathy: Results from a family-driven survey”.

Authors: A. Cossu, T. Lo Barco, J. Proietti, B. Dalla Bernardina, G. Cantalupo, L. Ghobert, I. Brambilla, E. Giarola, A. Costa, T. De Benito, S. Bethge, S. Cardot, Iga Montwill, E. Remonato, S. Gramaglia, F. Darra.

Contributors to the questionnaire: EUROPEAN KCNQ2 ASSOCIATION, KCNQ2 Einblick, Beratung, Netzwerk Germany, ASOCIACION KCNQ2 ESPANA, KCNQ2 FRANCE, Gruppo Facebook KCNQ2 POLSKA, DRAVET ITALIA ONLUS, with the support of CREP - Centro Ricerca Epilessie in età Pediatriche (Verona).





***To take great steps, we must not only act, but also
dream, not only plan, but also believe.***

Anatole France

OUR MISSION

Our goal is to support research, collect data for researchers, network with other associations in Europe and worldwide, and disseminate useful information to the KCNQ2 families

THE FOUNDER



*Alessandra
Costa*

Presidente



*Elisa
Remonato*

Vice Presidente



*Sara
Gramaglia*

Segretaria



*Anna
Accomando*

Socio-Fondatore



*Roberta
Brazzale*

Socio-Fondatore



*Peter Franz
Dorigotti*

Socio-Fondatore



*Isabella
Brambilla*

Socio-Fondatore

WHO WE ARE

The European KCNQ2 Association (E.K.A.)

was founded by seven Italian members, mothers and fathers of children affected by the genetic mutation KCNQ2 and suffering from rare epilepsies, with the aim of creating a network of collaborations in Europe between the various existing realities to support research projects and provide information to families.

THE NETWORK

- KCNQ2 Einblick, Beratung, Network Germany
- ASOCIACION KCNQ2 ESPANA,
- KCNQ2 FRANCE
- KCNQ2 CURE US
- KCNQ2 Poland (Facebook Group)
- KCNQ2 Denmark (Facebook Group)
- KCNQ2 The Czech Republic (Facebook Group)
- KCNQ2 The Netherlands (Facebook Group)

CONTACTS



europcankcnq2association@gmail.com
www.europcankcnq2association.com



Registered Office
Via Valerio Paitone, 27 - 25122 - Brescia
C.F. 98208650170

Support us with a donation
Banca Popolare di Sondrio Fil. Brescia
IBAN: IT 92 K 05696 11202 000004548 X84